Two-year safety data added to labeling from the company's STORM study. While Knoll reports that 70% of patients in the study maintained a 5% weight loss for the duration of the study compared to 44% of placebo patients, only safety data from the study was added to labeling. Meridia revised labeling states that the "safety and effectiveness...have not been determined beyond two years at this time." Previously, labeling limited the experience to one year from trials conducted for approval of the drug. Labeling also adds blood pressure data from a 26-patient study showing increases in systolic and diastolic blood pressure for the drug compared to placebo. Meridia labeling contains a warning about substantial increases in blood pressure. Meridia had sales of $94.5 mil. in 2000 compared to $201 mil. for Roche's Xenical, according to IMS Health data
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth